George C. McFarland, MSW Joins Evon Medics as Advisor
Mr. George McFarland joins the Evon Medics Advisory Board effective June 1, 2021. George brings his wealth of experience managing over $100 million in grants and contracts to promote health and human development. His network and experience working with numerous organizations throughout the United States to improve the quality of life in communities affected by health and social determined risks would also be valuable to Evon Medics as we continue to engage these underserved populations in our clinical trials.
National Institute on Aging issues $2.5m SBIR Phase II Financial Award to EvON Medics.
On April 29, 2021, the National Institute on Aging at the National Institutes of Health issued Small Business innovation Research (SBIR) Phase II award of $2.5m to EvON Medics for the Development and Evaluation of its Computerized Olfactory Training (COT) for the treatment of Alzheimer’s Disease. This is following encouraging results from the successful SBIR Phase I study.
Manuscript Publication: Comparative Effects of Repetitive Odor Identification and Odor Memory Tasks on Olfactory Engagement in Older Populations – A Pilot fMRI Study
On April 30, 2021, study results on the comparative effects of repititive odor identification and odor memory tasks on olfactory engagement in older populations was published in the Dovepress Journal. This study evaluated human Blood Oxygen Level-Dependent (BOLD) responses in primary and higher-order olfactory regions of older adults, using odor memory and odor identification tasks. The goal was to determine which olfactory and memory regions of interest are more strongly engaged in older populations comparing these two odor training tasks.
National Institute on Drug Abuse issues $1.7m SBIR Phase II Financial Award to EvON Medics.
On September 23, 2020, the National Institute on Drug Abuse at the National Institutes of Health issued Small Business innovation Research (SBIR) Phase II award of $1.7m to EvON Medics for the Development and Evaluation of its Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) for the treatment of Opioid Use Disorder. This is following a hugely successful SBIR Phase I study.
EvON Medics completes successful Phase I clinical trials
March 2020, EvON Medics completes a successful Phase I clinical trials for its Computerized Olfactory Training Program (COT), developed for preventing the development and progression of Alzheimer’s Disease (AD) and its Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT), developed for the management of the Opioid Use Disorder (OUD). Both solutions are home-based and user-friendly neuromodulatory devices.
National Institute on Aging Issues SBIR Financial Award to EvON Medics
On October 26, 2018, the National Institute on Aging at the National Institutes of Health issued Small Business innovation Research (SBIR) award to EvON Medics to support the development and evaluation of its computerized olfactory training program (COT) for cognitive decline in preclinical and early Alzheimer’s Disease (AD). COT is a key differentiating feature of the olfactory treatment delivery system (OTDS) platform developed by EvON Medics for treatment of a variety of brain conditions.